2025 annual financial data

Alnylam Pharmaceuticals 2025 Operating margin

Direct answer

Operating margin was 13.51%.

Operating income was 501.58M USD and net income was 313.75M USD.
Operating cash flow was 524.08M USD.

Get free Alnylam Pharmaceuticals email updates.

Bullstory sends one daily email when new analysis or important company news is available.

Verified data

Revenue
3.71B USD
Operating income
501.58M USD
Net income
313.75M USD
Operating cash flow
524.08M USD